Je-Gun Joung

6PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsInnate immunityGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 05, 2025
Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.

Junsik Park, Je-Gun Joung, Myong Cheol Lim

|Jul 15, 2022
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.

Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi

|May 14, 2022
Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer.

Yong Jae Lee, Ha Young Woo, Yoo-Na Kim

|Mar 23, 2022
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.

Jung-Yun Lee, Byoung-Gie Kim, Jae-Weon Kim

|Jun 02, 2021
Renal Cell Carcinoma-Infiltrating CD3low Vγ9Vδ1 T Cells Represent Potentially Novel Anti-Tumor Immune Players.

Hye Won Lee, Chanho Park, Je-Gun Joung

|Jul 17, 2019
Assessment of intratumoral heterogeneity with mutations and gene expression profiles.

Ji-Yong Sung, Hyun-Tae Shin, Kyung-Ah Sohn

Pageof 1

Frequent Collaborators

3 joint publications

Jung-Yun Lee

2 joint publications

Woong-Yang Park

2 joint publications

Byoung-Gie Kim

2 joint publications

Jae-Weon Kim